References
- RudwaleitMLandewéRvan der HeijdeDThe development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisalAnn Rheum Dis20096877077619297345
- RudwaleitMvan der HeijdeDLandewéRThe Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in generalAnn Rheum Dis201170253121109520
- SieperJvan der HeijdeDNon-radiographic axial spondyloarthritis: new definition of an old disease?Arthritis Rheum20136554355123233285
- WardMMDeodharAAklEAAmerican College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondy-loarthritisArthritis Rheumatol20166828229826401991
- DeodharAReveilleJDvan den BoschFThe concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the assessment of SpondyloArthritis international society in response to the US Food and Drug Administration’s comments and concernsArthritis Rheumatol2014662649265625154344
- European Medicines Agency [webpage on the Internet]Committee for Medicinal Products for Human Use2015Summary of opinion (post authorisation): Simponi (golimumab); 2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000992/WC500187055.pdfAccessed May 21, 2015
- van der HeijdeDDijkmansBGeusensPAnkylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)Arthritis Rheum20055258259115692973
- van der HeijdeDKivitzASchiffMHATLAS Study GroupEfficacy and safety of adalimumab in patients with ankylosing spondyli-tis: results of a multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheum2006542136214616802350
- CalinADijkmansBAEmeryPOutcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisAnn Rheum Dis2004631594160015345498
- LorenzinMOrtolanAFrallonardoPOlivieroFPunziLRamondaRPredictors of response and drug survival in ankylosing spondylitis patients treated with infliximabBMC Musculoskelet Disord20151616626205000
- SpadaroALubranoEMarchesoniARemission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre studyRheumatology (Oxford)2013521914191923878312
- ParkWYooDHJaworskiJComparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyArthritis Res Ther2016182526795209
- HaibelHRudwaleitMListingJEfficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-twoArthritis Rheum2008581981199118576337
- BarkhamNKeenHICoatesLCClinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitisArthritis Rheum20096094695419333933
- SieperJvan der HeijdeDDougadosMEfficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Ann Rheum Dis20137281582222772328
- DougadosMvan der HeijdeDSieperJSymptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheumatol2014662091210224891317
- LandewéRBraunJDeodharAEfficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 studyAnn Rheum Dis201473394724013647
- SieperJvan der HeijdeDDougadosMA randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisArthritis Rheumatol2015672702271226139307
- LubranoEPerrottaFMMarchesoniARemission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter studyJ Rheumatol20154225826325512483
- CorliJFlipoRMPhilippePTumor necrosis factor-α inhibition in ankylosing spondylitis and nonradiographic axial spondyloarthritis: treatment response, drug survival, and patient outcomeJ Rheumatol2015422376238226568593
- InmanRDDavisJCJrHeijdeDVEfficacy and safety of goli-mumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trialArthritis Rheum2008583402341218975305
- van der HeijdeDDeodharABraunJGO-RAISE InvestigatorsThe effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trialJ Rheumatol2014411095110324737912
- DeodharABraunJInmanRDGolimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE studyAnn Rheum Dis20157475776125387477
- SongIHWeißAHermannKGSimilar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trialAnn Rheum Dis20137282382523172749
- SieperJLenaertsJWollenhauptJEfficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1Ann Rheum Dis20147310110723696633
- DeodharAStrandVKayJBraunJThe term non-radiographic axial spondyloarthritis is much more important to classify to diagnose patient with axial spondyloarthritisAnn Rheum Dis20167579179426768406